XBI launched in 2006 as a smart beta biotech ETF
The SPDR S&P Biotech ETF (XBI) started trading on January 31, 2006. It is a smart beta product that tracks the S&P Biotechnology Select Industry Index. This ETF gives investors exposure to the health care sector through a modified equal weight structure. Instead of weighting stocks by market capitalization, it applies a different approach to stock selection.
Fund size and positioning in health care ETFs
XBI has grown to manage assets exceeding $9.75 billion. It is one of the largest ETFs in the health care category. The fund's strategy is built around non-cap-weighted indexing. It identifies biotech companies based on fundamental characteristics rather than company size alone. This allows investors to access a diversified set of firms in this high-risk, high-reward industry.
Cost efficiency enhances XBI's long-term potential
XBI has an annual expense ratio of 0.35%, making it a low-cost option among smart beta ETFs. Its 12-month trailing dividend yield stands at 0.39%, adding to its appeal. Lower fees can lead to stronger net returns over time. This makes XBI attractive to investors looking to minimize the drag of operating costs.
The S&P Biotechnology Select Industry Index is a subset of the S&P Total Markets Index, which includes all U.S. common stocks traded on major exchanges. The biotechnology component of this index is structured to reflect a balanced approach, aiming to capture companies with growth potential and favorable risk-return profiles.
XBI is sponsored by State Street Investment Management. It seeks to mirror the performance of its underlying index before fees and expenses. The ETF's holdings are transparent, with daily disclosures of the specific stocks it holds. This level of detail gives investors confidence in understanding the fund's composition and exposure.
Smart beta ETFs like XBI differ from traditional market cap-weighted funds. Instead of following the largest companies, they use alternative strategies such as equal weight, fundamental weight, or volatility-based weight. These approaches aim to outperform the market by focusing on select factors or traits.